The National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-has published a new book explaining ...
The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...
Add Yahoo as a preferred source to see more of our stories on Google. New research has found 'wide variation' in the use of prostate cancer testing across the UK. (Getty Images) (Korrawin via Getty ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
But our latest research shows that prostate cancer overdiagnosis from PSA screening is mainly a risk for men over the age of ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized ...
WASHINGTON (Reuters) - A urine test can help doctors better spot prostate cancer than either the current blood test or a rectal exam alone, U.S. researchers reported on Tuesday. They said Gen-Probe's ...
According to the World Cancer Research Fund, more than 100,000 men are newly diagnosed with prostate cancer annually in Japan, and a portion of those patients will be diagnosed with or later progress ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate ...
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results